One‐week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of <i>Helicobacter pylori </i>infection

Labenz, Joachim; Stolte, Manfred; Peitz, Ulrich; Tillenburg, B; Becker, T; Börsch, G

doi:10.1046/j.1365-2036.1996.727119000.x

Cited by 51 publications

(39 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Results of our prospective randomized study clearly show that triple therapy with omeprazole, amoxicillin and clarithromycin in DU disease is superior in efficacy to dual therapy with ompeprazole and clarithromycin as well as being well tolerated in Japanese patients. These results are compatible with those obtained in Western countries [1,10,11].…”

Section: Discussionsupporting

confidence: 83%

“…Resistance to nitroimidazoles is present in many patients before treatment in some countries and can be assumed to develop in most patients if nitroimidazole-containing regimen is unsuccessful [19,20]. Another promising regimen is triple therapy with omeprazole, amoxicillin and clarithromycin (OAC) [10,11]. The OAC regimen is appealing since in contrast to nitroimidazoles, H. pylori resistance to amoxicillin has not been reported.…”

Section: Discussionmentioning

confidence: 99%

“…One study [11] reported a high efficacy after 1 week of OAC regimen with low-dose clarithromycin (250 mg b.i.d. ), which is equivalent to the usual dosage for other bacterial infection.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Triple Therapy with Omeprazole, Amoxicillin and Clarithromycin Is Effective against Helicobacter Pylori Infection in Gastric Ulcer Patients as well as in Duodenal Ulcer Patients

Habu¹,

Mizuno²,

Hirano³

et al. 1998

Digestion

View full text Add to dashboard Cite

Background/Aims: There have been few reliable published studies permitting assessment of therapeutic regimens for Helicobacter pylori infection in gastric ulcer (GU) patients. The aim of the present study was to evaluate the efficacy of omeprazole-based dual and triple therapy regimens, both including clarithromycin, for the cure of H. pylori infection in active GU and duodenal ulcer (DU) patients. The study was conducted in Japan, a country in which GU is more prevalent than DU. Methods: Two hundred and thirty-four consecutive peptic ulcer patients (GU: n = 124; DU: n = 103; GDU: n = 7) suffering from H. pylori infection were randomly treated with either omeprazole 20 mg b.i.d. + amoxicillin 500 mg q.i.d. + clarithromycin 400 mg b.i.d. (OAC) or with omeprazole 20 mg b.i.d. + clarithromycin 400 mg b.i.d. (OC) for 14 days. H. pylori infection was evaluated by histology and culture from antral and corpus biopsies 6 weeks after completing antimicrobial therapy. Results: Follow-up data were available in 202 patients. The cure rates of H. pylori infection in GU patients were 83.9% (47/56) with OAC and 59.2% (29/49) with OC. Corresponding rates in DU patients were 91.5% (43/47) and 70.5% (31/44), respectively. The cure rates with OAC were significantly higher than those with OC (p < 0.001, χ² test). The cure rates in GU patients were lower than those in DU patients for both regimens, but these differences were not statistically significant. Side effects were generally mild and did not interfere with compliance. One patient in the OAC group and 2 patients in the OC group complained of severe side effects that led to therapy discontinuation. Conclusions: Triple therapy with omeprazole, amoxicillin and clarithromycin is a safe and effective regimen for the cure of H. pylori infection in GU patients as well as in DU patients. We recommend this triple regimen as a first-line treatment in all patients with peptic ulcers associated with H. pylori infection in Japan.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Triple Therapy with Omeprazole, Amoxicillin and Clarithromycin Is Effective against Helicobacter Pylori Infection in Gastric Ulcer Patients as well as in Duodenal Ulcer Patients

Habu¹,

Mizuno²,

Hirano³

et al. 1998

Digestion

View full text Add to dashboard Cite

show abstract

“…Diese Therapieschemata fª in 80 bis 100% der F~ille zu einer vollst~indigen Eradikation der H.-pylo¡ wobei sich die publizierten Daten ª auf den Protonenpumpenhemmer Omeprazol beziehen [4, 8, 10, 12, 15, 161. Insbesondere bei Cla¡ stenz bietet sich die Kombination von PPI, Amoxicillin und Metronidazol an [9,12,13,17].…”

Section: Ie Infektion Durch Das Spiralf6rmi-ge Bakte¡unclassified

Kurzzeit-Tripeltherapie mit Pantoprazol, Amoxicillin und Metronidazol bei Helicobacter-pylori-Infektion

Glaser

Hein

Daikeler³

et al. 1998

Med Klin

View full text Add to dashboard Cite

show abstract

“…Clarithromycin is the most effective single antibiotic available but frequently causes troublesome oral burning and taste disturbance (26) . More recently, the triple therapy with PPIs, clarithromycin, and either a nitroimidazole (tinidazole or metronidazole) or amoxicilin has been recommended (6,8,13,14) . This regimen is given twice a day, and 1 week of treatment may be as effective as 2 weeks.…”

Section: Introductionmentioning

confidence: 99%

The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy

Eisig¹,

André²,

Silva³

et al. 2003

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -Many of the currently used Helicobacter pylori eradication regimens fail to cure the infection due to either antimicrobial resistance or poor patient compliance. Those patients will remain at risk of developing potentially severe complications of peptic ulcer disease. Aim -We studied the impact of the antimicrobial resistance on the efficacy of a short course pantoprazole based triple therapy in a single-center pilot study. Methods -Forty previously untreated adult patients (age range 20 to 75 years, 14 males) infected with Helicobacter pylori and with inactive or healing duodenal ulcer disease were assigned in this open cohort study to 1 week twice daily treatment with pantoprazole 40 mg, plus clarithromycin 250 mg and metronidazole 400 mg. Helicobacter pylori was assessed at entry and 50 ± 3 days after the end of treatment by rapid urease test, culture and histology of gastric biopsies. The criteria for eradication was a negative result in the tests. Susceptibility of Helicobacter pylori to clarithromycin and metronidazole was determined before treatment with the disk diffusion test. Results -One week treatment and follow up were complete in all patients. Eradication of Helicobacter pylori was achieved in 35/40 patients (87.5%) and was higher in patients with nitroimidazole-susceptible strains [susceptible: 20/20 (100%), resistant: 10/ 15 (67%)]. There were six (15%) mild adverse events reports. Conclusions -A short course of pantoprazole-based triple therapy is well tolerated and effective in eradicating Helicobacter pylori. The baseline metronidazole resistance may be a significant limiting factor in treatment success.

show abstract

One‐week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection

Abstract: Simple and convenient 1-week triple therapies consisting of omeprazole, amoxycillin and either clarithromycin or metronidazole are sufficiently effective in eradicating H. pylori infection.

Cited by 51 publications

References 0 publications

Triple Therapy with Omeprazole, Amoxicillin and Clarithromycin Is Effective against Helicobacter Pylori Infection in Gastric Ulcer Patients as well as in Duodenal Ulcer Patients

Triple Therapy with Omeprazole, Amoxicillin and Clarithromycin Is Effective against Helicobacter Pylori Infection in Gastric Ulcer Patients as well as in Duodenal Ulcer Patients

Kurzzeit-Tripeltherapie mit Pantoprazol, Amoxicillin und Metronidazol bei Helicobacter-pylori-Infektion

The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy

Contact Info

Product

Resources

About